Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-209.84	-21.44	-38.35	-61.62	-51.75
Depreciation & Amortization	0.03	0.18	0.83	0.49	0.44
Stock-Based Compensation	1.04	3.33	5.43	5.57	4.48
Other Adjustments	183.68	1.97	-0.45	0.69	1.15
Changes in Accounts Payable	17.27	-1.33	-1.65	1.82	-1.32
Changes in Accrued Expenses	1.1	-3.14	-3.34	4.67	0.27
Changes in Other Operating Activities	-0.01	1.8	0.61	5.45	-5.58
Operating Cash Flow	-6.73	-18.62	-36.91	-42.93	-52.31
Capital Expenditures	-	-	-	-0.2	-0.22
Sale of Property, Plant & Equipment	-	-	0.08	-	-
Purchases of Investments	-	-	-25.94	-44.87	-84.21
Proceeds from Sale of Investments	-	11.65	48.18	57.45	36.38
Payments for Business Acquisitions	-17.37	-	-	-	-
Investing Cash Flow	-17.37	11.65	22.33	12.38	-48.05
Issuance of Common Stock	0.03	-	2.88	0.51	-
Net Common Stock Issued (Repurchased)	0.03	-	2.88	0.51	-
Issuance of Preferred Stock	266.81	-	-	-	-
Net Preferred Stock Issued (Repurchased)	266.81	-	-	-	-
Financing Cash Flow	266.84	-	2.88	0.51	-
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.71	-0.32	0.38	0.26	-0.92
Net Cash Flow	242.74	-6.97	-11.71	-30.04	-100.36
Free Cash Flow	-6.73	-18.62	-36.91	-43.13	-52.53
Free Cash Flow Per Share	-4.93	-16.09	-34.73	-42.43	-51.99
Levered Free Cash Flow	-191.44	-23.93	-41.89	-49.39	-58.16
Unlevered Free Cash Flow	-192.42	-24.7	-43.45	-48.98	-58.63

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q